This article is more than 5 years old. Information may no longer be current.

RegeneRx receives corneal wound healing patent in Hong Kong

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BETHESDA, Md. — The Hong Kong Intellectual Property Department has granted RegeneRx Biopharmaceuticals a patent for corneal wound healing using Tß4, analogues, isoforms and derivatives, RegeneRx announced in a press release.

The patent claims are based on substantial data supporting the use of Tß4 for wound healing of the cornea and other areas in and around the eye, the release said.

Tß4's corneal wound healing properties are being tested in a RegeneRx-sponsored phase 2 clinical trial of diabetic patients undergoing vitrectomy who often have difficulty healing quickly, if at all, after the procedure, according to the release.